NFE2L2 and Alzheimer disease: (150), i.p. administration of 0.5 and 1 mg/kg of the compound 5-hydroxy-2-methyl-1,4-naphthoquinone or plumbagin one hour before the first dose of STZ in a mouse model of STZ-induced AD, resulted in improving cognitive deficits, as assessed by MWM, through inhibition of the β-secretase enzyme and activation of the NRF2/ARE pathway.